Direct delivery

Preclinical proof-of-concept data for a Friedreich’s ataxia protein replacement therapy convinced Deerfield Management to lead a series A round for Chondrial Therapeutics Inc.

Chondrial raised the first undisclosed tranche of the $22.6 million round on Jan. 31. Wake Forest Innovation’s Catalyst Fund, which is managed by Pappas Capital, also participated. ...